Spastic Ataxia Composite ( SPAXCOM ): A Scale to Evaluate the Progression of Subjects with Spasticity and Ataxia

• Published in: Movement disorders
• Main Authors: Di Folco, Cécile, Dubec‐Fleury, Charlotte, Traschütz, Andreas, Kessler, Christoph, Reich, Selina, Gagnon, Cynthia, Lessard, Isabelle, Rodrigue, Xavier, Cocozza, Sirio, Satolli, Sara, Santorelli, Filippo M., Durr, Alexandra, Heinzmann, Anna, van de Warrenburg, Bart P., Willemse, Ilse H.J., Başak, A. Nazli, Vural, Atay, Brais, Bernard, Klebe, Stephan, Horvath, Rita, Schüle, Rebecca, Synofzik, Matthis, Tezenas du Montcel, Sophie
• Format: Journal Article
• Language: English
• Published: United States Wiley 20.08.2025
• Subjects: Life Sciences; Neurons and Cognition; spastic ataxia; SPG7; disease progression; ataxia; spastic ataxia Charlevoix‐Saguenay type
• ISSN: 0885-3185; 1531-8257; 1531-8257
• DOI: 10.1002/mds.70006

Current clinical scales that track disease progression are more tailored to spasticity or ataxia, with limited sensitivity to change. The aim was to develop a sensitive and valid scale specifically geared towards optimized sensitivity to change and adapted to patients presenting with both spasticity and ataxia. Longitudinal data from 127 spastic paraplegia type 7 (SPG7) and 112 autosomal recessive spastic ataxia Charlevoix-Saguenay (ARSACS) patients were collected within the multicenter PROSPAX study. Sensitivity to change over 2 years of 30 items from the Scale for the Rating and Assessment of Ataxias (SARA), Spastic Paraplegia Rating Scale (SPRS), and the Activities of Daily Living subscale of the Friedreich's Ataxia Rating Scale (FARS-ADL) was evaluated. Items that demonstrated the highest sensitivity to change were used to build the Spastic Ataxia Composite scale (SPAXCOM). With seven items, the SPAXCOM showed an effect size of 0.71, higher than reference scales (SARA: 0.43, SPRS: 0.42, FARS-ADL: 0.27). The SPAXCOM had a similar sensitivity to change for both genotypes and was more sensitive in participants with a SARA lower than 10 and within the intermediate disease stage (FARS-Disease Staging: 2-3.5). The SPAXCOM showed a high correlation with disease duration (r = 0.67 [0.60; 0.72]) and disease stage (r = 0.86 [0.83; 0.89]). Perception of improvement, stagnation, and worsening were associated with a mean yearly SPAXCOM change of 0.44 (-0.14; 1.01), 0.61 (0.19; 1.03), and 1.22 (0.96; 1.49), respectively. The SPAXCOM is more sensitive to change and homogeneous across genotypes than the reference scales, allowing a reduction of the required sample size in future clinical trials. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.